EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?EZH2 in normal hematopoiesis and hematological malignanciesHistone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and preventionEpigenetics in Cancer: A Hematological PerspectiveEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsNature and importance of follicular lymphoma precursors.Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.Chromatin proteins and modifications as drug targets.Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferationProteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.EZH2 in normal and malignant hematopoiesis.EZH2 as a potential target in cancer therapy.Genetic lesions in diffuse large B-cell lymphomasImmunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?A Multiplexed System for Quantitative Comparisons of Chromatin Landscapes.Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivationRole of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic TargetDifferential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemiaThe trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations.EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.EZH2 mutations are frequent and represent an early event in follicular lymphoma.Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome.Targeting oncogenic and epigenetic survival pathways in lymphoma.Molecular lesions in B-cell lymphoproliferative disorders: recent contributions from studies utilizing high-throughput sequencing techniques.B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies.Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.Targeted therapy of acute myeloid leukemia.Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.The molecular pathogenesis of B-cell non-Hodgkin lymphoma.Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia.Driver mutations of cancer epigenomes.Epigenetic dysregulation in follicular lymphoma.The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
P2860
Q24597424-C5037ADC-C969-4C59-B786-9C6DA442F432Q26779821-0A8D536B-570A-4020-9DC4-BF15B5403C91Q26994739-9F9221CD-79E9-4007-B535-8B09B8696541Q28077082-80E2781F-9B5A-487E-A807-AD1BF4C9BE0CQ29615392-A94A2CFD-3898-4884-9B09-4C75CD2D60EAQ33558757-BE4828FE-4019-4F8D-A05E-556D6890F517Q33586491-FA4F3D8D-7364-48A4-9411-C68BCBDE6975Q33959993-EF16FA7E-5D91-4797-ACDD-B268BFF07375Q34038652-0BA4C426-B597-402D-99A8-6E6851C45D47Q34317380-3E35113F-250E-417C-8D61-4CDA0DAE102CQ34342958-C95AE0B7-707A-40BF-B936-A6421EC8C354Q34375614-6B47DF50-A063-40EA-96B1-F36D894F4A3AQ35222823-333BCB34-8A27-46D6-A6BD-527F2C482C74Q35974341-530F7DDA-9BE8-4D90-8799-D63D96352266Q36140942-E00FCF7D-F62E-4622-BFD5-C0E635FC3711Q36450242-3AED7E5C-0C6E-496E-B868-561FEF781F12Q36625997-192215D1-5C46-48A1-8924-4F121EE38955Q36679745-F3FDBD19-EE27-47A2-BD3D-CA89CE1563F5Q36885677-26EB4041-2BE3-4339-82B8-97A35DDED597Q36892595-050D8670-342B-4E1D-B9CF-18F3B3B1E60BQ37210452-3DCEF059-ED49-4EDE-808F-B383720599C0Q37235726-9FAA6AC6-CEF4-41C6-88C6-BF1C39F5C104Q37272035-E758EE48-F56A-40E2-9B25-58B6284A5898Q37558207-89CD29DD-0629-4422-88ED-1A7F6EBD0567Q37729676-FDB29DEC-D856-4605-9CE5-7FE6D619B6F8Q38045799-C6BE9833-3AE8-41B4-98B1-42B0C05B62A2Q38084734-8942C880-A095-4886-A2D8-2CB796055D8CQ38095551-62474597-E46F-4EA8-8B92-2FA3C63D2F6DQ38185363-09594590-582E-4EB0-910D-1F17EDE78CDEQ38214120-F8052AF1-0420-458F-9C04-DE63B386BF65Q38261107-ECF24AC8-4EBE-442F-8634-3EE14A0A057CQ38333251-452D9F6B-802E-4A14-BEBA-FCD05C78785BQ38387178-7BD67266-08D3-4E9E-9C65-81D8FA95CB9FQ38495121-8EE452FE-F9AC-4AC9-919F-7A284E66EA83Q38594789-A02CA211-9253-413F-A37A-A04FE6AD9825Q38639828-7FE33E26-F14B-41F9-9226-CAD291AA13ABQ38677466-55EDF2B9-65FD-43BF-A14E-DBEDAE69FA4FQ38718857-32CB5ECF-BDEA-40A4-9B91-1EFE95B0BFAEQ38819164-E6381AC6-0EB4-49F5-ACC0-1B70EBB3B599Q38913027-7011FDE4-1EF6-4D86-9AAE-8D3095BEA1C7
P2860
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
@ast
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
@en
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
@nl
type
label
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
@ast
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
@en
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
@nl
prefLabel
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
@ast
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
@en
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
@nl
P2093
P2860
P3181
P1433
P1476
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
@en
P2093
A John Iafrate
Aliyah R Sohani
Bradley E Bernstein
Darrell Borger
Judith A Ferry
Lawrence R Zukerberg
Long Phi Le
Nancy Lee Harris
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0028585
P407
P50
P577
2011-12-14T00:00:00Z